Prostate Cancer Research Published

Dr. Adam Kinnaird

Dr. Adam Kinnaird has published two papers on prostate cancer in JAMA publications. He published "Prostate Cancer Among Black Men in Canada" in JAMA Network Open. Lead author Dr. Pat Albers says, “In our cohort study of men with prostate cancer in Alberta, we found that men who self-identified as Black had similar prostate cancer outcomes to men of other races, despite being diagnosed at a younger age, which underscores the benefit and need for risk adapted prostate cancer screening.” 

Dr. Kinnaird also published  "Fluorine-18 Prostate-Specific Membrane Antigen–1007 PET/CT vs Multiparametric MRI for Locoregional Staging of Prostate Cancer" in JAMA Oncology. Dr. Nik Mookerji, lead author says, "The paper's key points are:
Question  Is fluorine-18 prostate-specific membrane antigen–1007 positron emission tomography/computed tomography (¹⁸F-PSMA-1007 PET/CT) superior to multiparametric magnetic resonance imaging (MRI) for the locoregional primary staging of intermediate-risk and high-risk prostate cancers before treatment?

Findings  In this phase 2 prospective validating paired cohort study of 134 men undergoing radical prostatectomy, ¹⁸F-PSMA-1007 PET/CT correctly identified the final pathological tumor stage in 61 men (45%) compared to 38 men (28%) with multiparametric MRI, a statistically significant difference.
Meaning  These findings support the use of ¹⁸F-PSMA-1007 PET/CT in the pretreatment staging of intermediate-risk and high-risk prostate tumors, favoring its accuracy over multiparametric MRI.